ORIC Pharmaceuticals Grants 69,200 Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Globenewswire
- Employee Incentive Program: On December 1, 2025, ORIC Pharmaceuticals granted 69,200 non-qualified stock options and 11,400 restricted stock units to three new employees, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the clinical stage.
- Grant Conditions: The stock options have an exercise price equal to the closing price on the Grant Date, with 25% vesting on the one-year anniversary and the remainder vesting monthly thereafter, ensuring long-term employee commitment to the company.
- Compliance Assurance: The grants were approved by ORIC's Compensation Committee, adhering to Nasdaq Rule 5635(c)(4), which ensures compliance and transparency in talent acquisition, thereby boosting investor confidence.
- Strategic Implications: By implementing the 2022 Inducement Equity Incentive Plan, ORIC not only enhances employee loyalty but also secures human resources for future product development and clinical trials, supporting the company's long-term growth in the oncology market.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ORIC with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ORIC
Wall Street analysts forecast ORIC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORIC is 19.60 USD with a low forecast of 15.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
11 Buy
1 Hold
0 Sell
Strong Buy
Current: 10.980
Low
15.00
Averages
19.60
High
25.00
Current: 10.980
Low
15.00
Averages
19.60
High
25.00
About ORIC
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on improving patients’ lives by Overcoming Resistance In Cancer. The Company is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The Company's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent demand for registration-ready assets, positioning Oncolytics Biotech at the forefront of this growth wave.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy to drive the company's registration-directed programs in gastrointestinal cancers.
- Clinical Data Breakthrough: In third-line data for anal cancer, pelareorep achieved a 29% objective response rate, nearly tripling historical benchmarks, with a median duration of response reaching approximately 17 months, showcasing its potential in a setting with no FDA-approved treatment options.
- FDA Study Design Approval: Oncolytics has secured FDA alignment on its Phase 3 study design for first-line metastatic pancreatic cancer, positioning it to launch the only immunotherapy registration trial currently planned for this disease, further solidifying its market position.
Continue Reading
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
- Market Growth Potential: The precision oncology market is projected to surge from $110 billion to $225.65 billion, highlighting the industry's urgent need for registration-ready assets, positioning Oncolytics Biotech as a key investment opportunity.
- Executive Appointments: Oncolytics Biotech has appointed John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both bringing extensive experience in late-stage oncology trial execution and regulatory strategy, which will drive the company's registration programs in gastrointestinal cancers.
- Clinical Data Breakthrough: Pelareorep achieved a 29% objective response rate in third-line treatment, nearly tripling historical benchmarks in a setting with no FDA-approved treatment options, indicating significant clinical potential and likely accelerating the approval process for anal cancer.
- FDA Study Design Endorsement: Oncolytics has secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the company's unique position in the immunotherapy registration trial landscape and expected to drive future market opportunities.
Continue Reading